Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands
Targeted radionuclide therapy (TRT) is an emerging field and has the potential to become a major pillar in effective cancer treatment. Several pharmaceuticals are already in routine use for treating cancer, and there is still a high potential for new compounds for this application. But, a major issu...
Main Authors: | Kim E. de Roode, Lieke Joosten, Martin Behe |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/17/2/256 |
Similar Items
-
Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer
by: Michal Grzmil, et al.
Published: (2022-12-01) -
Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
by: Berthold A. Nock, et al.
Published: (2023-04-01) -
Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies
by: Joseph Lau, et al.
Published: (2022-08-01) -
Renal Disturbances during and after Radioligand Therapy of Neuroendocrine Tumors—Extended Analysis of Potential Acute and Chronic Complications
by: Marek Saracyn, et al.
Published: (2023-04-01) -
Renal Safety of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
by: Florian Rosar, et al.
Published: (2021-06-01)